Last reviewed 2026-06-01 · How we verify

Antibiotics + Corticosteroids

Antibiotics + Corticosteroids is a Antibiotic + Corticosteroid combination Small molecule drug developed by George Washington University. It is currently FDA-approved for Bacterial infections with significant inflammatory component (specific indication not clearly defined in available information). Also known as: Prednisone, Bactrim, Pentamidine, Atovaquone.

This combination product uses antibiotics to eliminate bacterial infection while corticosteroids suppress the inflammatory and immune response to reduce tissue damage and symptoms.

Antibiotics and corticosteroids are used together in various medical treatments, including for conditions such as atopic dermatitis and glaucoma, where they are administered as part of topical drops. The combination of these medications is classified as a small molecule modality, as per ChEMBL, and has been studied in clinical trials for various indications, including glaucoma and atopic dermatitis.

At a glance

Mechanism of action

Antibiotics work by killing or inhibiting bacterial pathogens through various mechanisms (cell wall disruption, protein synthesis inhibition, etc.), while corticosteroids reduce inflammation by suppressing immune cell activation and cytokine production. Together, they address both the infectious cause and the inflammatory consequences of bacterial infection.

Approved indications

• Bacterial infections with significant inflammatory component (specific indication not clearly defined in available information)

Common side effects

• Infection-related adverse events (from antibiotic component)
• Immunosuppression-related adverse events (from corticosteroid component)
• Gastrointestinal disturbances
• Increased susceptibility to secondary infections

Key clinical trials

• Pulmonary Condensate: Non-invasive Evaluation of Pulmonary Involvement in Asthma and Cystic Fibrosis.
• Dual-light Antibacterial Photodynamic Therapy as an Adjunctive Treatment to Corticosteroid Treatment in OLP (NA)
• A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation (PHASE2)
• Intravenous Immunoglobulin for the Treatment of Acute Exacerbations of Idiopathic Pulmonary Fibrosis (PHASE3)
• Antibiotics vs Corticosteroids in Treatment of Granulomatous Lobular Mastitis (PHASE1, PHASE2)
• Hydrocortisone and Fludrocortisone for the Treatment of Septic Shock (PHASE4)
• Nasal Steroids, Irrigation, Oral Antibiotics, and Subgroup Targeting for Effective Management of Acute Sinusitis (PHASE4)
• Evaluation of the Efficacy of Corticosteroids in Septic Arthritis in Adults (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Antibiotics + Corticosteroids CI brief — competitive landscape report
• Antibiotics + Corticosteroids updates RSS · CI watch RSS
• George Washington University portfolio CI

Frequently asked questions about Antibiotics + Corticosteroids

Related

• Drug class: All Antibiotic + Corticosteroid combination drugs
• Manufacturer: George Washington University — full pipeline
• Therapeutic area: All drugs in Infectious Disease / Immunology
• Indication: Drugs for Bacterial infections with significant inflammatory component (specific indication not clearly defined in available information)
• Also known as: Prednisone, Bactrim, Pentamidine, Atovaquone, Primaquine/Clindamycin

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing